Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MajesTEC-4 maintenance study of teclistamab with or without lenalidomide versus lenalidomide alone after autologous stem cell transplant in newly diagnosed multiple myeloma
MOH_2024-06-10_013122Phase 3Recruiting
- Sponsor
- European Myeloma Network
- Start
- Nov 2023
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Teclistamab + Lenalidomide, Lenalidomide alone and Teclistamab alone (3 arms). Started Nov 2023; status: recruiting.
02
Drugs
teclistamablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2024-06-10_013122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-06-10_013122.